API
![ʻO ka paʻakai maʻemaʻe kiʻekiʻe (R)-[(3-ethoxy-1-methyl-3-oxoprop-1-enyl)amino]phenylacetate ma ke kumu kūʻai maikaʻi.](https://ecdn6.globalso.com/upload/p/689/image_product/2024-04/661cf240b167b43209.png)
Mea hana maʻemaʻe kiʻekiʻe CAS 1197-18-8 Tranexamic Acid
ʻO ka waika tranexamic, i kapa ʻia hoʻi ka waika tranexamic, he derivative synthetic o lysine me kahi ʻano like me tyrosine. Hoʻopaʻa ʻia e nā hoʻokolohua lapaʻau, kūpono ia no nā ʻano ʻili āpau a hiki ke wehe i ka pigmentation, keʻokeʻo, a me nā wahi māmā, e like me: pigmentation ma hope o ka ʻike ʻana o ka lā, nā wahi ʻeleʻele (chloasma, freckles, senile lentils, etc.), ʻili koʻikoʻi, Acne a me ka mumū, ka mālama hope ʻana ma hope o ka laser, ka mālama ʻana i nā kukui pulsed, a me nā mea ʻē aʻe. No laila, hiki ke hāʻawi ʻia ka waika tranexamic no ka hoʻohana ʻana i nā mea hoʻonaninani e like me ka creams, lotions, essences, lotions, a me nā pale maka.
ʻO ka waikawa Tranexamic kahi lāʻau antifibrinolytic synthetic amino acid e hiki ai ke hoʻokūkū i ka hoʻopaʻa ʻana o ka lysine i ka fibrin i ka plasmin, a laila e kāohi ai i ka lysis o nā fibrin clots a hana i ka hemostasis. Hoʻohana nui ʻia ia i ka clinically. No nā ʻano koko like ʻole ma muli o ka hyperfibrinolysis.
ʻO ka hoʻohana ʻana i ka waika Tranexamic
1. ʻO ka waikawa Tranexamic kahi lāʻau anti-fibrinolytic, hiki iā ia ke mālama i nā kahe koko a me ka maʻi maʻi a loaʻa ka hemostasis.
Hiki i ka 2.Tranexamic acid ke ho'ēmi i ka hana melanin: Hiki iā ia ke hoʻokūkū pololei me ka tyrosine i loko o nā pūnaewele, ke kāohi i ka hopena catalytic o ka tyrosine metabolism, a ho'ēmi i ka hana melanin.
3. Kāohi i ka angiogenesis: Hiki iā ia ke hoʻokūkū pololei me ka tyrosine i loko o nā pūnaewele, ke kāohi i ka hopena catalytic o ka tyrosine metabolism, a ke kāohi i ka angiogenesis ʻili. Hiki i kēia ke hoʻemi i ka nui o nā kīʻaha koko i loko a a puni nā chloasma lesions, hoʻemi i ka hiki ʻana mai o nā hopena inflammatory, a laila hoʻemi i ka hoʻokumu mau ʻana o ka chloasma.
Hiki i ka 4.Tranexamic acid ke ho'ēmi i ka hōʻikeʻana o nā cytokines pro-inflammatory a me nā chemokines e hana i nā hopena anti-inflammatory, hiki ke pale pono i ka hopena o nā maʻi maʻi a hoʻemi i ka hanaʻana o ka'ekene.
5. Loaʻa i ka waika Tranexamic ka Anti-kahiko a me ka anti-photoaging waiwai. Hoʻonui ia i ka synthesis hyaluronic acid ma ka hoʻonui ʻana i ka helu o nā cell epidermal, hoʻemi i ka hoʻohaʻahaʻa ʻana o ka matrix extracellular i loko o ka dermis ma ke kāohi ʻana i ka plasmin, a hiki ke hoʻemi i nā pae o kekahi mau mea oxidative i loko o ke koko e hoʻomaikaʻi i ka ʻelemakule maoli o ka ʻili. Hoʻomaikaʻi i ka UVB-induced photoaging ma o ka hoʻonui ʻana i ka biogenesis mitochondrial, hoʻoponopono i ka huna ʻana o ka hormone ma o ka hoʻonui ʻana i ka hōʻike ʻana o nā mea loaʻa estrogen ma ka ʻili o nā mast cell, a me ka hoʻomaikaʻi ʻana i ka photoaging UVA-induced.
ʻO Tranexamic acid ka wehewehe ʻana
Hebei WeiBang Biotechnology Co., Ltd
| inoa mea kūʻai | ʻakika Tranexamic | CAS No | 1197-18-8 |
| La Hana Hana | 2023/12/01 | Lā Hōʻike | 2023/12/01 |
| Ka nui | 10,000KG | La hoao | 2023/12/01 |
| BatchNo | WB20231201 | Ola ola | 2 makahiki |
| Nā mea ho'āʻo | Hōʻike | ||
| Ka nana aku | ʻO ka pauka aniani keʻokeʻo | ||
| ʻIkepili | A ME | ||
| Pohō ma ka maloʻo | ≤0.50% | ||
| pH | 7.0-8.0 | ||
| Hoʻāʻo | ≥99.0 | ||
| Lehu sulphated | ≤0.10% | ||
| Mea pili | haumia A: ≤0.10% | ||
| haumia B: ≤0.20% | |||
| ʻO nā mea haumia ʻē aʻe: ≤0.10% | |||
| ʻO nā mea haumia ʻē aʻe: ≤0.20% | |||
| Klorida | ≤140ppm | ||
| Ka helu ʻana o ka pā | ≤1000cfu/g | ||
| hū & poʻo | ≤100cfu/g | ||
| ʻO Pb | ≤10mg/kg | ||
| As | ≤2mg/kg | ||
| Hg | ≤1mg/kg | ||
| Cd | ≤5mg/kg | ||
| Ka hopena | Kupono | ||